Moderna, Inc. (MRNA) News
Filter MRNA News Items
MRNA News Results
|Loading, please wait...|
MRNA News Highlights
- For MRNA, its 30 day story count is now at 99.
- Over the past 27 days, the trend for MRNA's stories per day has been choppy and unclear. It has oscillated between 1 and 27.
- The most mentioned tickers in articles about MRNA are DRUG, NGL and ROSE.
Latest MRNA News From Around the Web
Below are the latest news stories about Moderna Inc that investors may wish to consider to help them evaluate MRNA as an investment opportunity.
Biotechnology behemoth Moderna Inc. (MRNA) reported stellar fourth quarter and full-year fiscal 2021 results, outpacing both revenue and earnings expectations by a huge margin. Shares soared 15.1% on the news closing at $156.23 on February 24. Moderna’s COVID-19 vaccine, Spikevax, has received full U.S. FDA approval, and its revenue was boosted majorly by Spikevax-related sales. Yet, shares of one of the best coronavirus vaccine stocks, MRNA, lost 33.5% year-to-date vis-à-vis gaining 5.3% over the past year. Additionally, the company’s board of directors announced a new share buyback program of $3 billion. Stellar Results Moderna’s Q4-diluted earnings of $11.29 came in significantly higher than analysts' estimates of $9.90 per share.
Moderna has to focus on the rest of its pipeline to keep MRNA stock relevant and profitable as Covid vaccine revenues taper off by 2023.
Yahoo Finance's Anjalee Khemlani discusses the CDC's new guidelines for COVID-19 mask-wearing.
In this article, we will take a look at the 10 companies that topped profit expectations. You can skip our detailed analysis of these companies and go directly to the 5 Companies That Topped Profit Expectations. Notable stocks from the consumer cyclical sector, including Booking Holdings Inc. (NASDAQ:BKNG), eBay Inc. (NASDAQ:EBAY) and Bath & Body […]
The advisory committee to the European Union's drug regulator on Friday said it has recommended reducing the interval between the second dose and booster dose of Moderna Inc's COVID-19 vaccine from six months to three months. Several countries including Greece and France have previously shortened the interval between the first two doses and the booster dose of COVID-19 vaccines, in the face of rising cases due to the Omicron variant. The European Medicines Agency (EMA) in December said data supported safe and effective administration of a booster as early as three months after a two-shot regimen, without changing the six month recommendation.
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
U.S. responds to Russia’s Ukraine invasion with more sanctions, Moderna sees fourth Covid-19 vaccine dose this fall, Morgan Stanley confirms federal probes of block-trading business, and other news to start your day.
An advisory panel of the European Medicines Agency ("EMA") has recommended that Moderna's (MRNA +11.5%) COVID-19 vaccine be authorized for children 6 to 11 years old. The recommendation from the Committee for Medicinal Products for Human Use is based on data from a study in the age group showing that that the...
While headlines out of Ukraine continue to dominate Wall Street, earnings news provided a catalyst for a large number of single-stock moves in Thursday's midday trading. Moderna (NASDAQ:MRNA) and Nikola (NASDAQ:NKLA) both rallied on earnings reports and product updates. Live Nation (NYSE:LYV) also showed an advance during intraday action, boosted...
The following slide deck was published by Moderna, Inc. in conjunction with their 2022 Q4 earnings call....